- Home
- PEPG vs FHTX Comparison
PEPG vs FHTX Comparison
Compare PEPG & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEPG | FHTX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.4M | 173.4M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PEPG | FHTX |
|---|---|---|
| Price | $2.39 | $2.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $10.19 | $6.00 |
| AVG Volume (30 Days) | 779.4K | ★ 987.0K |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.61 | 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.31 | $1.79 |
| 52 Week High | $7.80 | $7.61 |
Technical Indicators
Market Signals| Indicator | PEPG | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 16.48 |
| Support Level | $1.60 | N/A |
| Resistance Level | $2.62 | $5.35 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 21.60 | 12.43 |
Price Performance
Historical ComparisonAbout PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.